© 1995 American Heart Association, Inc.
Articles |
Rapamycin Selectively Inhibits Angiotensin II–Induced Increase in Protein Synthesis in Cardiac Myocytes In Vitro
Potential Role of 70-kD S6 Kinase in Angiotensin II– Induced Cardiac Hypertrophy
From the Cardiovascular Research Center, Division of Cardiology, University of Michigan Medical Center, Ann Arbor.
Correspondence to Dr Seigo Izumo, Cardiovascular Research Center, 7220-MSRB3, University of Michigan Medical Center, Ann Arbor, MI 48109-0644.
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Abstract It has been suggested that phosphorylation of a 40S ribosomal protein, S6, regulates protein synthesis. Two distinct families of S6 kinase have been identified, the rsk-encoded 85- to 92-kD S6 kinase (RSK) and the 70- or 85-kD S6 kinase (p70S6K). We have previously shown that hypertrophic stimuli, such as angiotensin II (Ang II), rapidly activate RSK in cardiac myocytes. However, RSK and p70S6K are regulated by distinct mechanisms, and p70S6K, but not RSK, is the physiological S6 kinase in vivo in other cell types. Using cultured neonatal rat ventricular myocytes, we examined whether Ang II activates p70S6K and investigated the effect of rapamycin, a potent yet indirect inhibitor of p70S6K, on the Ang II–induced hypertrophic response. Immunoblot analyses indicate that cardiac myocytes express the 70- and 85-kD forms of p70S6K. Ang II caused a rapid and sustained activation of p70S6K through the type I Ang II receptor. Rapamycin inhibited Ang II–induced activation of p70S6K in a dose-dependent manner, with an IC50 of 0.14 ng/mL (0.15 nmol/L). Rapamycin did not inhibit Ang II–induced activation of tyrosine kinase, mitogen-activated protein kinase, RSK, and protein kinase C. The effect of rapamycin is unlikely to be mediated by its effect on p34cdc2 and p33cdk2 because Ang II did not activate these cell cycle–dependent kinases in cardiac myocytes. In contrast, a dose-dependent inhibition of p70S6K by rapamycin is very closely correlated with its inhibition of the Ang II–induced increase in protein synthesis. Interestingly, rapamycin did not affect the Ang II–induced activation of specific gene expression, including the immediate-early gene c-fos and fetal type genes, such as atrial natriuretic factor and skeletal
-actin. Moreover,
rapamycin did not suppress Ang II–induced phenotypic changes at the
protein level, such as increased atrial natriuretic factor
secretion, expression of ß-myosin heavy chain, and organization
of actin into sarcomeric units. These results indicate that
p70S6K is activated by Ang II and that a
rapamycin-sensitive signaling mechanism, most likely
p70S6K, plays an essential role in the Ang
II–induced increase in overall protein synthesis but not in Ang
II–induced specific phenotypic changes in cardiac myocytes.
Key Words: cardiac hypertrophy • 70-kD S6 kinase • angiotensin II • protein synthesis • rapamycin
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cardiac hypertrophy is a fundamental adaptive process in response to hemodynamic overload. It is well known that external load plays a critical role in determining muscle mass and its phenotype, but accumulating evidence suggests that cardiac hypertrophy induced by growth factors mimics most, if not all, aspects of load-induced cardiac hypertrophy.1 2 3 For example, load-induced hypertrophy in ventricular myocytes in vitro and in vivo is associated with induction of immediate-early genes, such as c-fos, c-jun, and c-myc, which is followed by activation of fetal-type genes, such as ANF, skeletal
-actin, and ß-MHC genes.1 2 3 4 5 Very similar
phenotypic changes are observed in cardiac hypertrophy
induced by Ang II, endothelin-1, basic fibroblast growth factor, and
phenylephrine.3 6 7 8 9 We have previously shown
that mechanical stretch of neonatal cardiac myocytes causes autocrine
secretion of Ang II and that this initiates the hypertrophic response
in vitro.10 Ang II, in turn, modulates the expression of
various growth factors, such as transforming growth
factor-ß1.7 Thus, growth factors seem to
play an essential role in the pathogenesis of load-induced cardiac
hypertrophy. In contrast to the wealth of knowledge of the hypertrophic effects of various growth factors, the specific roles of intracellular signal transduction molecules in mediating the phenotypic changes associated with cardiac hypertrophy remain poorly characterized. We11 and others12 have previously shown that mechanical stretch and Ang II13 14 activate multiple intracellular second messenger systems, such as phospholipases C, D, and A2, tyrosine kinases, p21ras, MAP kinases, RSK, and PKC in neonatal rat cardiac myocytes in vitro. However, the precise role of each second messenger system has not been established. Recently, by use of the microinjection technique, a "dominant negative" form of p21ras and a specific antibody against the Gq-type GTP binding protein have been shown to inhibit phenylephrine-induced cardiac hypertrophic responses (such as increase in cell size, transcriptional activation of ANF, and organization of actin filaments), thereby indicating that p21ras and Gq are essential in phenylephrine-induced hypertrophy.15 16 More recently, inhibition of the MAP kinase or Raf-1 by transfection or microinjection of a dominant negative form of MAP kinase or Raf-1 has been shown to inhibit phenylephrine-induced transcriptional activation of ANF and MLC-2 but not to suppress organization of actin filaments by phenylephrine.17 18 These results suggest that each second messenger system may have a different role in the cardiac hypertrophic response.
Increased protein synthesis is the cardinal feature of cardiac hypertrophy. Protein synthesis is regulated by various molecules that interact with the translational machinery of the ribosome.19 Among them, S6, a component of 40S ribosomal proteins, is located at the interface between 40S and 60S ribosomal proteins and may interact directly with mRNA.20 Accumulating evidence suggests that multiple serine phosphorylations of S6 at the carboxy terminus regulate the rate of protein synthesis by stimulating initiation and elongation of protein translation.20 The S6 phosphorylation at the carboxy terminus is mediated by a family of serine/threonine kinases, known as S6 kinases. The S6 kinases consist of two distinct families, RSK and p70S6K.20 21 22 Several lines of evidence suggest that RSK and p70S6K are regulated by distinct signaling pathways. For example, RSK is phosphorylated and activated by MAP kinases, but p70S6K is not.21 23 24 25 Although both RSK and p70S6K phosphorylate S6 at the same serine residues in vitro, recent studies suggest that p70S6K, not RSK, is the physiological kinase that phosphorylates S6 in vivo in Swiss 3T3 cells.25
Recently, it has been shown that a subnanomolar concentration of the macrolide rapamycin specifically binds to a cellular protein termed FKBP and blocks activation of p70S6K in response to cytokines.25 26 27 After microinjection of a polyclonal antibody against p70S6K or treatment with rapamycin, it has been suggested that p70S6K plays an essential role in G1 to S progression during the cell cycle in various cell types.25 26 28 29 However, rapamycin was also shown to inhibit two cell cycle–dependent kinases, p33cdk2 and p34cdc2.27 30 Therefore, at present, it is not clear whether rapamycin inhibits cell growth primarily by its effect on p70S6K or on these cell cycle–dependent kinases.
Neonatal cardiac myocytes in serum-free culture are in a terminally differentiated state and do not reenter the cell cycle. Upon growth factor stimulation, these cells undergo hypertrophy without cell division.1 2 3 Therefore, cardiac myocytes provide a unique opportunity to probe the function of p70S6K by rapamycin, without its confounding effect on G1-S and G2-M progressions, which are controlled by p33cdk2 and p34cdc2, respectively.31 Therefore, the present study was conducted to examine (1) whether Ang II activates p70S6K in cardiac myocytes, (2) the effects of rapamycin on Ang II–induced p70S6K activation as well as Ang II–induced activation of other signaling molecules, and (3) the effects of rapamycin on Ang II–induced increase in protein synthesis as well as phenotypic changes in cardiac myocytes.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Materials
Protein A–Sepharose was purchased from Pharmacia Biotech. S6 peptide (RRRLSSLRA) was from UBI. Phosphocellulose units were from Pierce. GS peptide (PLSRTLSVAAKK) and PKC pseudosubstrate peptide [PKC (19-36)] were from Bachem. Histone H1 was from Boehringer Mannheim. Immobilon-P was from Millipore. Ang II and the RIA kit for ANF were from Peninsula. Sep-Pak C18 columns were from Waters. Losartan and PD123319 were gifts from Du-Pont Merck and Parke-Davis, respectively. Rapamycin was a gift from Wyeth-Ayerst Research. The stock solution of rapamycin was freshly prepared with ethanol before experiments as 1000-fold concentrated solution. All other chemicals were purchased from Sigma Chemical Co. A recombinant anti-phosphotyrosine antibody (RC20H) was purchased from Transduction Laboratories. Anti-p70S6K polyclonal antibody (C-18), anti-RSK polyclonal antibody (C-21), and anti–MAP kinase polyclonal antibodies (anti-ERK-1 [K-23] and anti-ERK-2 [C-14]) were purchased from Santa Cruz Biotechnology. Another polyclonal anti-p70S6K antibody (C-2) was a gift from Dr J. Blenis, Harvard Medical School. Rabbit anti-p34cdc2 serum was purchased from GIBCO. Anti-p33cdk2 monoclonal antibody was a gift from Dr E. Harlow, Massachusetts General Hospital Cancer Center. Rabbit anti-mouse IgG antibody and normal rabbit serum (nonimmune serum) were purchased from Jackson Immuno Research.
Cell Culture
Primary culture of the neonatal rat cardiac myocyte was
prepared as previously described.5 7 After an enzymatic
dissociation, the cells were preplated for 1 hour to selectively enrich
for cardiac myocytes. The resultant suspension of myocytes was plated
onto gelatin-coated 35- or 60-mm culture dishes at a density of
1.5x105 cells per square centimeter and cultured in
DMEM/F-12 (GIBCO) (1:1 [vol/vol]) supplemented with 5% horse serum,
2 g/L bovine serum albumin (fraction V), 3 mmol/L pyruvic acid,
15 mmol/L HEPES (pH 7.6), 100 µmol/L ascorbic acid, 100 µg/mL
ampicillin, 4 µg/mL transferrin, 0.7 ng/mL sodium selenium, and 100
µmol/L bromodeoxyuridine. The culture medium was changed 24 hours
after seeding to a defined serum-free DMEM/F-12 medium that had the
same composition as described above, except that 5% horse serum and
bromodeoxyuridine were not added. The use of the preplating procedure,
mitogen-poor serum for plating (5% horse serum),
bromodeoxyuridine, high cell-plating density, and a prompt switch
to the serum-free medium enabled us to routinely obtain myocyte
cultures in which >90% were myocytes, as assessed by
immunofluorescence staining with a monoclonal
antibody against sarcomeric MHC (MF-20).32 Cardiac
fibroblast culture was prepared as previously
described.5 7 All experiments were performed in the
serum-free conditions 48 hours after changing to the serum-free
medium.
Immunoprecipitation and Immunoblotting
For immunoblotting of p70S6K,
cell lysates were prepared by an addition of 1 mL of ice-cold lysis
buffer A containing (mmol/L) potassium phosphate 10 (pH 7.4), EDTA 1,
EGTA 5, MgCl2 10, ß-glycerophosphate 50, sodium
orthovanadate 1, dithiothreitol 2, and AEBSF 1, along with 10 nmol/L
okadaic acid, 100 µmol/L leupeptin, 10 µg/mL aprotinin, and 0.5%
Triton X-100. Lysates containing equal amounts of protein (750 µg)
were incubated with 1 µg of polyclonal antibody against
p70S6K (C-18) raised against C terminus (485-502) of the
rat 70-kD S6K for 2 hours at 4°C. In some experiments, a preabsorbed
antibody was used for immunoprecipitation. Preabsorbtion of the
antibody was performed by incubating the antibody with a 10-fold higher
concentration of the antigen peptide for 12 hours at 4°C. The immune
complex was precipitated by protein A–Sepharose, and the
immunoprecipitates were electrophoresed on an 8%
polyacrylamide gel and were then transferred to Immobilon-P
membranes. Membranes were blocked with 5% bovine serum albumin
in TBST solution (containing 20 mmol/L Tris [pH 8.0], 150 mmol/L
NaCl, and 0.05% Tween 20) for 2 hours. Membranes were then incubated
with the same anti-p70S6K antibody at 1 µg/mL in
blocking solution or with polyclonal antisera raised against the
predicted C terminus (502-525) of the p70S6K
(C-2)25 at a dilution of 1:500 in TBST. Immunoreactive
bands were probed with 125I–protein A, and blots were
subjected to autoradiography.
Immunoblotting of phosphotyrosine was performed as
described previously by using a horse radish peroxidase–conjugated
recombinant anti-phosphotyrosine antibody (RC20H).14
An enhanced chemiluminescence system (Amersham) was used as a detection
system.
Immune Complex S6 Kinase Assay
RSK and p70S6K activities were measured with an
immune complex kinase assay using S6 peptide (RRRLSSLRA)
corresponding to amino acids 231 to 239 of human S6 as a substrate.
This peptide has been shown to be a good substrate for
RSK.33 However, it contains the consensus recognition
sequence of p70S6K [R-(R)-R-X-X-S-X],34 and
it has been shown to be a good substrate for p70S6K as
well.35 The cell-free lysates were prepared with
buffer A. The lysates containing equal amounts of protein (750 µg)
were incubated with 1 µg of anti-RSK antibody (C-21) or 1 µg of
anti-p70S6K antibody (C-18 or C-2) for 2 hours at
4°C. Protein A–Sepharose was then added, and the immunoprecipitates
were washed with buffer A three times. Kinase reaction (25 µL) was
performed in conditions inhibitory to cyclic
nucleotide–dependent protein kinases and
Ca2+-dependent protein kinases by incubating the
immunoprecipitates with 12.5 µL of 2x kinase buffer containing
(mmol/L) MOPS 50 (pH 7.2), ß-glycerophosphate 120,
p-nitrophenylphosphate 60, EGTA 10, MgCl2 30,
dithiothreitol 2, and sodium orthovanadate 2, along with 2 µmol/L
protein kinase inhibitor (rabbit sequence), 6.25 µL
of ATP mixture containing 40 µmol/L cold ATP and 5 µCi
[
32P]ATP (6000 Ci/mmol), and 1.25 µL of 5 mmol/L S6
peptide for 20 minutes at 30°C. To terminate the reaction, samples
were spotted onto phosphocellulose units (Pierce) and washed twice by
centrifugation with 75 mmol/L phosphoric acid. The
filters were then placed into scintillation vials, and the
radioactivity was counted.
MAP Kinase, PKC, and Histone H1 Kinase Assays
The immune complex in-gel MAP kinase assay, the PKC assay in
permeabilized cells, and the immune complex histone H1
kinase assay were performed as described
previously.13 14 36 The specificity of the PKC assay has
been described previously.37
Measurement of Protein Content, Rate of Protein Synthesis, and
Protein Degradation
Cardiac myocytes were plated on 35-mm dishes and cultured in the
serum-free condition for 48 hours before the experiments. After
stimulation of myocytes, each dish was rinsed three times with PBS. The
cell layer was scraped with 1 mL of 1x standard sodium citrate
containing 0.25% (wt/vol) SDS and vortexed extensively. Total cell
protein and the DNA content were determined by the Lowry method and the
Hoechst dye method, respectively, and the protein content was
normalized by the DNA content to correct for small differences in the
cell number between dishes as described previously.5
As an index of protein synthesis, [3H]phenylalanine incorporation was measured as described previously.5 Cardiac myocytes were pretreated with rapamycin or vehicle (0.1% ethanol) for 30 minutes. The myocytes were then incubated with 5 µCi/mL of [3H]phenylalanine (120 Ci/mmol) and unlabeled phenylalanine (0.36 mmol/L) in the medium and treated with or without Ang II in the presence of rapamycin or vehicle. The cells were washed with PBS, and 10% TCA was added at 4°C for 60 minutes to precipitate protein. The precipitate was washed three times with 95% ethanol and then resuspended in 0.15N NaOH. Aliquots were counted by a scintillation counter.
Protein degradation was determined as described previously.38 To radiolabel cellular proteins, cardiac myocytes were incubated with 10 µCi/mL of [3H]phenylalanine for 4 hours. The myocytes were then washed with nonradioactive medium containing excess concentrations (500 µg/mL) of phenylalanine three times at 30-minute intervals. Some dishes were then harvested with 10% TCA to determine "zero time" values. After pretreatment with rapamycin (10 ng/mL) or vehicle (0.1% ethanol) for 30 minutes, some dishes were maintained for an additional 24 hours in control medium containing excess nonradioactive phenylalanine (500 µg/mL) to minimize reutilization of label, and others were maintained for an identical period in the same medium plus Ang II (100 nmol/L) and/or rapamycin (10 ng/mL). After 24 hours of incubation, all dishes were harvested with 10% TCA. TCA precipitates were treated as described above and counted by scintillation counter.
Northern Blot Analysis
Isolation of total cellular RNA and Northern blot analysis
were performed as described previously.5 7 The probes for
skeletal -actin, ANF, and GAPDH were used as described
previously.5 The hybridization signals of specific mRNAs
were normalized to those of GAPDH mRNA to correct for differences in
loading and/or transfer.7
RIA
Cardiac myocytes were plated on 35-mm dishes (7x105
cells per dish). After 48 hours of culture in the serum-free
medium, myocytes were treated with rapamycin (10 ng/mL) or vehicle
(0.1% ethanol) for 30 minutes and then stimulated with Ang II (100
nmol/L) for 24 hours. ANF production was defined as the amount
of ANF released into the medium during a 60-minute period after 24
hours of incubation with Ang II as described previously.39
At 24 hours, the medium was removed from the culture and replaced with
2.5 mL of fresh medium. After 60 minutes, 2 mL of the medium was
collected. EDTA (1 mg/mL) was added, and after a 5-minute
centrifugation at 1000g, the supernatant was
stored at -20°C. The sample was partially purified by using a
Sep-Pak C18 column as described previously10
and lyophilized. The samples were redissolved in the RIA buffer, and
RIA was performed according to the manufacturer's instructions
(Peninsula). Repeated RIAs of a control sample indicate that the
interassay variations were <5%.
Analysis of MHC Isoforms
MHCs were analyzed by using a method described by Fauteck
and Kandarian,40 which enabled separation of - and
ß-MHCs on a 5% denaturing SDS-PAGE gel. Because considerable
expression of ß-MHC protein is still observed in the neonatal rat
heart,41 T3 (2 ng/mL) was applied throughout
the experiment to suppress the basal expression of ß-MHC protein.
From day 4, Ang II (100 nmol/L) was applied every 12 hours in the
presence of rapamycin (10 ng/mL) or vehicle (0.1% ethanol) for 5 days.
Rapamycin was applied every other day when the culture media were
changed. On day 9, myocytes grown on six-well plates were washed
with PBS three times and scraped with 200 µL per well of PBS
containing 1 mmol/L EDTA. Approximately 30 000 cells (10 µL of the
PBS suspension) were treated with Laemmli loading buffer and boiled for
10 minutes. SDS-PAGE was performed at 4°C by using a 5%-separating
gel that was 20 cm in length. A running buffer was recirculated to keep
its pH constant. The gel was then transferred to the Immobilon-P
filter, and immunoblot analysis was performed by
using antibody against sarcomeric myosin (MF-20, 1:25
dilution).32 The heart homogenates from
adult and fetal rats were used to identify - and ß-MHCs,
respectively. Densitometric analysis was performed with
INTELLIGENT QUANTIFIER (Bio Image).
Immunostaining
Cells were cultured on gelatin-coated glass coverslips. Cells
were treated with rapamycin (10 ng/mL) or vehicle alone (0.1% ethanol)
for 30 minutes and then Ang II (100 nmol/L) as required. The cells were
maintained for 24 hours before fixation. Cells were washed with PBS,
fixed with 3.6% formaldehyde in PBS for 10 minutes,
permeabilized with 0.3% Triton X-100 in PBS for 10
minutes, and blocked in 1% ovalbumin plus 0.1% Tween 20
for 30 minutes. The cells were stained with fluorescein
isothiocyanate–conjugated phalloidin (Sigma, 40 µg/mL in PBS,
0.5% NP-40, and 2 mg/mL bovine serum albumin), washed in PBS
and 0.1% Tween 20, and mounted for fluorescence microscopy as
described previously.17
Statistics
Data are given as mean±SEM. Statistical analysis was
performed by ANOVA as appropriate. Post-test multiple comparison
was performed by the method of Bonferroni. Significance was accepted at
the P<.05 level.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Expression of p70S6K in Cardiac Myocytes
We first examined expression of p70S6K protein in cardiac myocytes. Immunoprecipitation was performed by using a specific polyclonal anti-p70S6K antibody (C-18), and after SDS-PAGE of the immunoprecipitates, immunoblot analysis was performed by using the same antibody. In the control state (Fig 1
, lane 1), multiple bands were
observed at 
70 kD. After longer exposure (bottom panel), bands were
also detected at 85 kD. Both of these bands were significantly
attenuated when the immunoprecipitation was performed with the
anti-p70S6K antibody preabsorbed with 10-fold excess of
the antigen peptide (lane 5). The remaining band at 70 kD in lane 5 is
unlikely to be a nonspecific band, because no band was seen when the
immunoprecipitation was performed with a rabbit polyclonal antibody
against RSK (C-21, lane 6). These bands were not observed at all when
the preabsorbed antibody was used in immunoblotting
(data not shown). This suggests that these bands correspond to 70-kD
(II) and 85-kD (I) forms of p70S6K.25
Interestingly, after a 2-minute stimulation of cardiac myocytes with
Ang II (100 nmol/L), multiple bands having reduced mobility were
observed above the 70- and 85-kD bands (lanes 2 to 4). It has been
shown that p70S6K is observed as multiple bands (70 and
85 kD) on immunoblotting, depending on its
phosphorylation state of several
residues.25 Therefore, it is likely that both 70- and
85-kD forms of p70S6K are phosphorylated
upon stimulation with Ang II. We did not detect bands at 90 kD,
confirming that the antibody we used does not cross-react with
RSK.
|
Ang II Activates p70S6K
To examine whether p70S6K is activated upon
stimulation with Ang II, in vitro kinase assays were performed with S6
peptide used as a substrate. To eliminate other kinases that
phosphorylate S6 peptide, such as RSK and
PKC,33 the kinase assay was performed after
immunoprecipitation with the antibody against p70S6K (C-18
or C-2). As shown in Fig 2, an increase in
phosphorylation of S6 peptide was observed after 3
minutes of stimulation with Ang II (100 nmol/L), and this persisted for
>60 minutes. S6 peptide phosphorylation observed in
immunoprecipitates with an antibody preabsorbed with the antigen
peptide was as low as the background level and did not increase after
stimulation with Ang II, suggesting that the S6 peptide
phosphorylation observed in the immunoprecipitate with
the anti-p70S6K antibody was specific to
p70S6K.
|
) or with preabsorbed
anti-p70S6K antibody (
). The peptide
phosphorylation by the p70S6K immune
complex at time zero is designated as 1.0. The results are
representative of three independent experiments
performed in duplicate. B, Myocytes were pretreated with or without
losartan (5 µmol/L) or PD123319 (5 µmol/L) for 90 minutes
and then treated with or without Ang II (100 nmol/L) for 10 minutes.
The immune complex p70S6K assay was performed as described
above. S6 peptide phosphorylation by p70S6K
immune complex obtained from control myocytes without any
antagonists is designated as 1.0. The results shown are
mean±SEM obtained from four samples each. *P<.001 compared
with respective control.
The Ang II (100 nmol/L)–induced increase in p70S6K
activity was suppressed by losartan (5 µmol/L), an Ang II
type-1 receptor antagonist, but not by PD123319 (5
µmol/L), an Ang II type-2 receptor antagonist (Fig 2B
). We used 50-fold higher doses of the
antagonists because they have lower affinity to the
receptors than does Ang II. The result suggests that Ang II–induced
p70S6K activation is mediated by the Ang II type-1
receptor.
Rapamycin Suppresses p70S6K Activation by Ang
II
We next examined effects of rapamycin on Ang II–induced
p70S6K activation. Cardiac myocytes were treated with
various concentrations of rapamycin (0.03 to 30 ng/mL [33 pmol/L to 33
nmol/L]) for 30 minutes and then treated with or without Ang II (100
nmol/L) for 10 minutes, and the p70S6K activity was
measured by the immune complex S6 peptide kinase assay. As shown in Fig 3A, rapamycin inhibited both basal and Ang II–induced
p70S6K activity in a dose-dependent manner, with
half-maximum inhibition doses at 0.68 and 0.14 ng/mL, respectively.
The Ang II–induced increase in p70S6K activity was
completely suppressed at >1 ng/mL of rapamycin.
|
To examine the effect of rapamycin on the
phosphorylation state of p70S6K,
p70S6K immunoprecipitates were immunoblotted
with the anti-p70S6K antibody (C-18) after SDS-PAGE. As
shown in Fig 3B, in rapamycin-treated myocytes,
faster migrating bands were observed at 70 kD (and also at 85 kD
after long exposure of the blot [not shown]), and the upward shift of
the bands by the Ang II treatment was abolished. This suggests that
rapamycin induces dephosphorylation of
p70S6K in the basal condition and also suppresses Ang
II–induced phosphorylation of p70S6K.
Rapamycin Does Not Affect Ang II–Induced Activation of Tyrosine
Kinase, MAP Kinase, RSK, or PKC
To examine the specificity of rapamycin, effects of the drug on
Ang II–induced activation of other second messenger systems were
examined. We have shown that Ang II causes tyrosine
phosphorylation of several proteins at least in part by
activating tyrosine kinase activity in cardiac myocytes.14
Rapamycin, however, did not affect the Ang II–induced increase in
tyrosine phosphorylation of proteins such as p42, p44,
and p75-80 (peak phosphorylation at 5 minutes [Fig 4A]) and p120-130 (peak phosphorylation
at 1 minute [Fig 4A and data not shown]). We have
also shown that Ang II activates MAP kinases and subsequently
another distinct S6 kinase, RSK.14 However, it has been
suggested that p70S6K and RSK are regulated by different
signaling mechanisms in other cell systems.21 23 24 25
Therefore, we examined whether rapamycin affects activation of MAP
kinases and RSK by Ang II. MAP kinase activity was assessed by the
immune complex in-gel MAP kinase assay. As shown in Fig 4B, rapamycin did not affect the Ang II–induced
increase in MAP kinase activity at 44- and 42-kD proteins, which are
ERK-1– and ERK-2–related MAP kinases, respectively.14
RSK activity was assessed by the immune complex kinase assay using S6
peptide as a substrate. RSK was immunoprecipitated with an anti-RSK
antibody (C-21). Rapamycin did not significantly affect the basal
activity of RSK or the Ang II–induced activation of RSK (Fig 4C), indicating that rapamycin specifically inhibits
p70S6K among the family of S6 kinases.
|
We have previously shown that Ang II activates PKC and that PKC
plays an essential role in Ang II–induced c-fos gene
expression.13 Therefore, we examined effects of rapamycin
on Ang II–induced activation of PKC. PKC activity was assessed by the
permeabilized cell assay using a synthetic
peptide, glycogen synthase (GS) peptide, as a substrate. As shown in
Fig 5A, a 2-minute stimulation of cardiac myocytes with
Ang II significantly increased phosphorylation of the
GS peptide, whereas this increase in phosphorylation
was largely inhibited in the presence of the PKC pseudosubstrate
peptide. Ang II–induced increase in phosphorylation of
GS peptide was not affected by the treatment with rapamycin (10 ng/mL),
suggesting that rapamycin does not inhibit PKC.
|
In other cell systems, signaling molecules (other than
p70S6K) thus far reported to be sensitive to rapamycin are
two cyclin-dependent kinases, p34cdc2 and
p33cdk2.27 30 We examined whether Ang II
activates these kinases in cardiac myocytes. Myocytes were
treated with or without Ang II (100 nmol/L) for 18 hours.
Immunoprecipitation was performed with anti-p34cdc2 or
-p33cdk2 antibody, and the immunoprecipitates were
subjected to the histone H1 kinase assays. As shown in Fig 5B, control myocytes had very low activity of these
kinases, and its level did not change after stimulation with Ang II
(lanes 1, 2, 6, and 7). In contrast, an 18-hour treatment of cardiac
fibroblasts with fetal calf serum (FCS, 20%) significantly increased
kinase activity of p34cdc2 and p33cdk2 toward
histone H1 (lanes 3, 5, 8, and 10). This increased kinase activity was
not observed in the immunoprecipitates prepared with nonimmune serum
(lanes 4 and 9). This suggests that kinase activity in the
immunoprecipitates was in fact due to p34cdc2 or
p33cdk2 and that the apparent absence of induction of
histone H1 kinase activity of p34cdc2 and
p33cdk2 in cardiac myocytes after Ang II stimulation was
not due to a technical problem. These results suggest that the effects
of rapamycin are not mediated by inhibition of these
cyclin-dependent kinases in cardiac myocytes.
Rapamycin Inhibits the Ang II–Induced Increase in Protein
Content
We next examined the effects of rapamycin on the Ang
II–induced increase in protein synthesis. Cardiac myocytes were
pretreated with various concentrations of rapamycin or vehicle alone
(0.1% ethanol) for 30 minutes and were then stimulated with or without
Ang II (100 nmol/L) for 24 hours. Ang II caused a modest but highly
consistent increase in the protein content over 24 hours. Ang
II–induced increase in protein content was observed at 1 nmol/L
(13.8±2.1%, n=4, P<.05), the lowest concentration we
examined, and reached a peak at 100 nmol/L (19.3±0.1%, n=7,
P<.01; Fig 6A, left). The results confirm
our previous observations that Ang II causes hypertrophy of
cardiac myocytes. Interestingly, rapamycin at >0.3 ng/mL completely
suppressed the Ang II (100 nmol/L)–induced increase in the protein
content. Rapamycin at 10 ng/mL reduced the protein content in the basal
level as well. This is not a general toxic effect of rapamycin, because
an increase in the protein content caused by FCS was not affected by
rapamycin (10 ng/mL) (Fig 6A, right).
|
We next examined the effects of rapamycin on the rate of protein
synthesis and protein degradation. The rate of protein synthesis was
determined by [3H]phenylalanine incorporation over 24
hours. As shown in Fig 6B, rapamycin at 1 ng/mL
significantly suppressed the Ang II–induced increase in
[3H]phenylalanine incorporation, and rapamycin at 10
ng/mL significantly suppressed both basal and Ang II–induced
[3H]phenylalanine incorporation. Rapamycin, however, did
not significantly change protein degradation over 24 hours in the
presence or absence of Ang II (Fig 6C). These results
indicate that rapamycin inhibits the Ang II–induced increase in
protein content by inhibiting the rate of protein synthesis but not by
increasing the rate of protein degradation.
Rapamycin Does Not Affect Other Ang II–Induced Hypertrophic
Responses
We next examined whether rapamycin affects other hypertrophic
phenotypes mediated by Ang II, such as induction of
immediate-early genes and activation of the "fetal"-type gene
program.7 As shown in Fig 7A, the rapid
accumulation of c-fos mRNA in response to Ang II was not
affected by rapamycin. Ang II–induced upregulation of the fetal type
genes, such as ANF and skeletal -actin, was also observed even
in the presence of rapamycin (10 ng/mL) (Fig 7B), which
completely suppressed the Ang II–induced increase in
p70S6K activity (Fig 3A) as well as cardiac
protein content (Fig 6A).
|
To examine the effect of rapamycin on the Ang II–induced phenotypic
change in protein level, the level of ANF production in cardiac
myocytes was determined by measuring the rate of accumulation of ANF in
the culture media over 60 minutes.39 Conditioned media
were collected from myocytes treated with or without Ang II in the
presence of rapamycin or vehicle alone, and the ANF content was
determined by RIA after a partial purification with Sep-Pak
C18 columns. As shown in Fig 7C, the rate
of ANF secretion by myocytes treated with Ang II for 24 hours was
significantly higher than that in control myocytes treated with
vehicle. This increase in ANF accumulation was observed in the presence
of rapamycin (10 ng/mL), suggesting that rapamycin does not inhibit
the increased expression of ANF protein.
We next examined the effect of rapamycin on the Ang II–induced isoform
switch of MHC. Because a significant amount of ß-MHC is expressed in
the control state in neonatal myocytes, we added a
physiological concentration of T3 (2
ng/mL) to the medium throughout the experiments in order to accelerate
"maturation" of neonatal myocytes in vitro.41
Myocyte extracts were subjected to SDS-PAGE on 5% gel, which enabled
separation of - and ß-MHC on denaturing conditions,40
and then immunoblotted with anti–sarcomeric myosin
antibody (Fig 7D). In control myocytes, almost all MHC
protein was -isoform (lane 1). Ang II stimulation increased the
expression of ß-MHC (lane 4), indicating that Ang II promotes an
isoform switch of MHC in cardiac myocytes in vitro, although a more
extensive isoform switch was not possible in this experimental
condition. Treatment of myocytes with rapamycin (10 ng/mL) did not
affect basal (lane 2) or Ang II–induced increase in ß-MHC expression
(lane 3).
We finally examined the effect of rapamycin on Ang II–induced
reorganization of contractile proteins into sarcomeric units, another
important characteristic of load-induced and growth
factor–induced cardiac hypertrophy.2 17
This effect was examined by staining filamentous actin with
fluorescently labeled phalloidin. Fig 8a shows
control myocytes, and Fig 8c shows rapamycin (10
ng/mL)–treated myocytes maintained in a serum-free medium without
Ang II. The actin of these myocytes is generally not well organized.
Fig 8b shows myocytes treated with Ang II for 24 hours.
After Ang II treatment, the number of myocytes that show organized
sarcomeric actin (visible as discrete fluorescent bands)
significantly increased. This Ang II–induced organization of actin was
also observed in myocytes treated with Ang II in the presence of
rapamycin (10 ng/mL) (Fig 8d). Highly organized
sarcomeric actin was observed in 17, 63, 14, and 54 of 100 randomly
selected myocytes in each staining shown in Fig 8a, 8b, 8c, and 8d, respectively.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Phosphorylation of S6 by p70S6K has been shown to stimulate incorporation of mRNA into polysomes, thereby stimulating initiation of protein translation.19 20 In the present study, we show that Ang II causes a rapid and sustained activation of p70S6K in cardiac myocytes. Interestingly, the macrolide rapamycin inhibited Ang II–induced activation of p70S6K without affecting Ang II–induced activation of known signaling pathways. Rapamycin suppressed the Ang II–induced increase in the protein content with a dose dependence that was similar to that for its inhibition of p70S6K. On the other hand, rapamycin did not suppress Ang II–induced phenotypic changes at both the mRNA and protein levels. These results suggest that the increase in overall protein synthesis and specific phenotypic changes in cardiac hypertrophy are regulated by different mechanisms and that activation of a rapamycin-sensitive signaling molecule, most likely p70S6K, may be involved in the Ang II–induced increase in the protein synthesis in cardiac myocytes.
Rapamycin exerts its effect by high-affinity binding to a cellular receptor protein designated FKBP, one of the immunophilins.27 FKBP is an evolutionarily conserved protein and the only known cellular receptor for rapamycin (Reference 2727 and S.L. Schreiber, Harvard University, personal communication, 1995). Recently, cellular targets of the rapamycin-FKBP complex have been identified in yeast and mammals. These proteins, referred to as TORs or RAFTs, have considerable amino acid sequence similarity to PI-3 kinase, and it has been postulated that the effect of rapamycin might be mediated by inhibition of RAFT1 PI-3 kinase activity.27 42 43 Thus, the point of action by a subnanomolar concentration of rapamycin is specific, and p70S6K and cyclin-dependent protein kinases (p33cdk2 and p34cdc2) are the only signaling molecules thus far reported to be inhibited by the FKBP-rapamycin complex (References 27 and 3027 30 and S.L. Schreiber, personal communication, 1995). We found that rapamycin suppresses p70S6K activity at very low concentrations (IC50, 0.14 ng/mL [0.15 nmol/L]) but does not suppress Ang II–induced activation of tyrosine kinase, MAP kinase, RSK, or PKC, even at concentrations that completely suppress Ang II–induced activation of p70S6K. Furthermore, Ang II does not activate p33cdk2 or p34cdc2 in cardiac myocytes, as determined by the immune complex histone H1 kinase assay. Thus, it is unlikely that the effect of rapamycin is mediated by inhibition of these cyclin-dependent kinases. Therefore, as far as we examined, the inhibitory effect of rapamycin is best explained by its effects on p70S6K among the Ang II–regulated early signaling molecules in cardiac myocytes. However, we cannot formally exclude the possibility that rapamycin may affect an as-yet-unidentified signaling molecule(s) that is regulated by RAFTs.
As an alternative approach to obtain a specific inhibition of p70S6K, transfection of a dominant negative form of the kinase or microinjection of a blocking antibody could be considered. To our knowledge, however, a dominant negative form of p70S6K has not been reported. Furthermore, microinjection of a blocking antibody against p70S6K may not be informative in this case, because p70S6K inhibition is expected not to suppress the known markers of Ang II–induced hypertrophy that can be used at a single cell level (ie, increases in ANF expression and sarcomeric assembly). Therefore, despite its potential limitation, rapamycin is a highly useful tool for studying the signal transduction mechanism of cardiac hypertrophy, because it is able to segregate tyrosine kinase–dependent, MAP kinase–dependent, RSK-dependent, and PKC-dependent signaling pathways from the rapamycin-sensitive signaling mechanism, most likely p70S6K, in cardiac myocytes.
Microinjection of activated p21ras into cardiac myocytes has been shown to cause hypertrophic responses, such as an increase in cell size and induction of c-fos, ANF, and MLC-2.15 In other cell systems, a p21ras-dependent protein kinase cascade has been shown to play a critical role in growth factor–induced MAP kinase activation.21 In cardiac myocytes, it has been recently shown that transfection or microinjection of a dominant negative form of MAP kinase (ERK-1) inhibits phenylephrine-induced gene expression, such as c-fos, ANF, and MLC-2.15 Therefore, it is possible that the p21ras-induced phenotypic changes in cardiac myocytes may require MAP kinase and its downstream S6 kinase, RSK. However, our results suggest that activation of MAP kinase is not sufficient to initiate an increase in protein content, because Ang II–induced MAP kinase activation was still observed in the presence of rapamycin. Because p70S6K is activated in Ras-transformed cells,44 it is possible that the increase in cell size induced by p21ras may be mediated by p70S6K. It has been shown that RSK has wide substrate specificity and phosphorylates transcription factors, such as Fos and serum response factor in addition to S6.20 21 On the other hand, p70S6K phosphorylates almost exclusively S6.20 Therefore, it is likely that each signaling molecule has different roles and that activation of various signaling molecules in concert mediate the hypertrophic response.
We have shown that rapamycin inhibits the Ang II–induced increase in
overall protein content but not other Ang II–induced hypertrophic
responses. For example, rapamycin did not inhibit Ang II–induced
expression of an immediate-early gene, c-fos, or
fetal-type genes, such as ANF and skeletal -actin.
Interestingly, rapamycin does not affect Ang II–induced phenotypic
changes at the protein level either; increases in ANF
production, ß-MHC induction, and reorganization of actin
filaments were observed in the presence of rapamycin. Interestingly, it
has been suggested that phosphorylation of S6 at the
carboxy terminal sites might induce translation of only a specific
class of mRNAs, which are characterized by having a polypyrimidine
tract at their 5' cap sites. These mRNAs include elongation factors and
ribosomal protein mRNAs.45 It is conceivable that
inhibition of p70S6K by rapamycin might exert its effect by
selectively inhibiting translation of mRNAs that encode regulators of
protein translation whose increased expression is required for the Ang
II–induced increase in the protein content. It is also interesting to
note that mRNAs of ANF, skeletal -actin, and ß-MHC lack a 5'
polypyrimidine tract,46 47 48 raising the possibility that
their translation may be regulated by a different mechanism.
At present, we do not know how p70S6K is
activated in response to Ang II stimulation in cardiac
myocytes. Although a wide variety of stimuli have been shown to
activate p70S6K in other cell systems, the
mechanism of p70S6K activation is not well
understood.23 25 49 50 Although a 10-minute treatment of
cardiac myocytes with phorbol 12-myristate 13-acetate (1
µmol/L), an activator of PKC, activated
p70S6K (2.75-fold increase versus control, n=3; authors'
unpublished data, 1995), Ang II–induced activation of
p70S6K was not affected by high concentrations of the
general protein kinase inhibitor H-7 (100 µmol/L;
authors' unpublished data, 1995), which we have shown to inhibit the
Ang II–induced activation of PKC activity.13 Therefore,
at least H-7–sensitive isoforms of PKC may not be essential for Ang
II–induced p70S6K activation. Similarly, both
p21ras-dependent and -independent mechanisms
have been reported for p70S6K activation in other cell
systems.44 50 We have recently shown that Ang II
activates p21ras (authors' unpublished
data, 1995), but at present, we do not know whether Ang II–induced
p70S6K activation is p21ras
-dependent or not. It has been recently shown that PI-3 kinase plays an
essential role in p70S6K activation induced by
platelet-derived growth factor.49 Considering the
recent report that the ß subunit of the G protein directly
mediates PI-3 kinase activation in myeloid-derived
cells,51 it is possible that agonists for G
protein–coupled receptors directly activate PI-3 kinase,
thereby causing activation of p70S6K. Therefore, it would
be interesting to examine the role of PI-3 kinase in Ang II–induced
p70S6K activation and Ang II–induced increase in protein
content in cardiac myocytes.
Our results indicate that induction of c-fos is not sufficient to cause the Ang II–induced increase in protein synthesis in cardiac myocytes. Schunkert et al52 have recently shown that in the isolated perfused adult rat heart, Ang II causes an increase in the rate of protein synthesis without inducing c-fos expression. These results indicate that c-fos expression may not be essential for the increase in protein synthesis. However, induction of c-fos gene expression may play a role in other aspects of cardiac hypertrophy, such as induction of the genes regulated by the AP-1 transcription factor complex.5
Finally, it should be noted that different growth factors seem to use different mechanisms for regulating protein synthesis. We found that the increased protein content stimulated by Ang II is rapamycin-sensitive, but that stimulated by FCS is not. We confirmed that FCS also activates p70S6K, which is inhibited by rapamycin in cardiac myocytes (authors' unpublished data, 1995). This suggests that molecules other than p70S6K also mediate the serum-induced increase in the protein content. It is interesting to note that MAP kinase has been implicated in the regulation of protein translation by phosphorylating the rat PHAS-I (phosphorylated heat- and acid-stable proteins regulated by insulin) after exposure of adipocytes to insulin. These proteins are thought to prevent initiation of protein translation by interacting with the translation initiation factor eIF-4E, but their phosphorylation relieves the translation inhibition.53 It has been also shown that Ang II induces phosphorylation of eIF-4E itself through a PKC-dependent mechanism in vascular smooth muscle.54 Because rapamycin did not affect activation of MAP kinase or PKC in cardiac myocytes, it is unlikely that rapamycin affects these signaling mechanisms in our system. However, it is likely that protein translation is regulated by multiple mechanisms, and further studies are necessary to elucidate the precise mechanism of the increase in protein synthesis by hypertrophic stimuli in cardiac myocytes.
|
Selected Abbreviations and Acronyms |
|---|
|
|
Acknowledgments |
|---|
A part of this study was supported by a Charles King Trust Fellowship of the Medical Foundation (Dr Sadoshima) and an Established Investigator Award of the American Heart Association (Dr Izumo). We thank Drs J. Blenis and E. Harlow for antibodies, Dr T. Kulik for the critical reading of the manuscript, Dr S. Schreiber for advice on the specificity of rapamycin, Dr S. Sehgal for providing rapamycin, and Dr J. Metzger for advice on MHC isoform analysis.
Received July 24, 1995; accepted September 6, 1995.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Morgan HE, Baker KM. Cardiac hypertrophy. Circulation. 1991;83:13-25.
2. Chien KR, Knowlton KU, Zhu H, Chien AS. Regulation of cardiac gene expression during myocardial growth and hypertrophy: molecular studies of an adaptive physiologic response. FASEB J. 1991;5:3037-3046. [Abstract]
3. Schneider MD, Parker TG. Cardiac growth factors. Prog Growth Factor Res. 1991;3:1-26. [Medline] [Order article via Infotrieve]
4. Komuro I, Yazaki Y. Control of cardiac gene expression by mechanical stress. Annu Rev Physiol. 1993;55:55-75. [Medline] [Order article via Infotrieve]
5.
Sadoshima J, Jahn L, Takahashi T, Kulik TJ, Izumo
S. Molecular characterization of the stretch-induced
adaptation of cultured cardiac cells: an in vitro
model of load-induced cardiac hypertrophy.
J Biol Chem. 1992;267:10551-10560.
6. Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Annu Rev Physiol. 1992;54:227-241. [Medline] [Order article via Infotrieve]
7.
Sadoshima J, Izumo S. Molecular
characterization of angiotensin II–induced
hypertrophy of cardiac myocytes and hyperplasia of cardiac
fibroblasts: a critical role of the AT1 receptor
subtype. Circ Res. 1993;73:413-423.
8.
Shubeita HE, McDonough PM, Harris AN, Knowlton KU,
Glembotski CC, Brown JH, Chien KR. Endothelin induction of
inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene
expression in ventricular hypertrophy.
J Biol Chem. 1990;265:20555-20562.
9.
Simpson PC. 1-Adrenergic-stimulated
hypertrophy in neonatal rat heart muscle cells. In: Toshima
H, Maron BJ, eds. Hypertrophic
Cardiomyopathy, Cardiomyopathy
Update: Series 2. Tokyo, Japan: University of Tokyo Press;
1989:73-96.
10. Sadoshima J, Xu Y, Slayter HS, Izumo S. Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell. 1993;75:977-984. [Medline] [Order article via Infotrieve]
11. Sadoshima J, Izumo S. Mechanical stretch rapidly activates multiple signal transduction pathways in cardiac myocytes: potential involvement of an autocrine/paracrine mechanism. EMBO J. 1993;12:1681-1692. [Medline] [Order article via Infotrieve]
12.
Yamazaki T, Tobe K, Hoh E, Maemura K, Kaida T, Komuro
I, Tanemoto H, Kadowaki T, Nagai R, Yazaki Y. Mechanical
loading activates mitogen-activated protein kinase
and S6 peptide kinase in cultured rat cardiac myocytes.
J Biol Chem. 1993;268:12069-12076.
13.
Sadoshima J, Izumo S. Signal transduction
pathways of angiotensin II–induced c-fos gene
expression in cardiac myocytes in vitro: roles of
phospholipid-derived second messengers.
Circ Res. 1993;73:424-438.
14.
Sadoshima J, Qiu Z, Morgan JP, Izumo S.
Angiotensin II and other hypertrophic stimuli mediated by G
protein–coupled receptors activate tyrosine kinase,
mitogen-activated protein kinase, and 90-kD S6 kinase in
cardiac myocytes: the critical role of
Ca2+-dependent signaling.
Circ Res. 1995;76:1-15.
15.
Thorburn A, Thorburn J, Chen S-Y, Powers S, Shubeita
HE, Feramisco JR, Chien KR. HRas-dependent pathways can
activate morphological and genetic markers of cardiac muscle
cell hypertrophy. J Biol Chem. 1993;268:2244-2249.
16.
LaMorte VJ, Thorburn J, Absher D, Spiegel A,
Brown JH, Chien KR, Feramisco JR, Knowlton KU. Gq-
and ras-dependent pathways mediate hypertrophy of
neonatal rat ventricular myocytes following
1-adrenergic stimulation. J Biol
Chem. 1994;269:13490-13496.
17.
Thorburn J, Frost JA, Thorburn A.
Mitogen-activated protein kinases mediate changes in gene
expression, but not cytoskeletal organization associated with cardiac
muscle cell hypertrophy. J Cell
Biol. 1994;126:1565-1572.
18.
Thorburn J, McMahon M, Thorburn A. Raf-1 kinase
activity is necessary and sufficient for gene expression changes but
not sufficient for cellular morphology changes associated with cardiac
myocyte hypertrophy. J Biol
Chem. 1994;269:30580-30586.
19. Kimball SR, Vary TC, Jefferson LS. Regulation of protein synthesis by insulin. Annu Rev Physiol. 1994;56:321-348. [Medline] [Order article via Infotrieve]
20. Stewart MJ, Thomas G. Mitogenesis and protein synthesis: a role for ribosomal protein S6 phosphorylation? Bioessays. 1994;16:809-815. [Medline] [Order article via Infotrieve]
21.
Blenis J. Signal transduction via the MAP
kinases: proceed at your own RSK. Proc Natl Acad Sci U S
A. 1993;90:5889-5892.
22.
Erikson RL. Structure, expression, and
regulation of protein kinases involved in the
phosphorylation of ribosomal protein S6.
J Biol Chem. 1991;266:6007-6010.
23. Ballou LM, Luther H, Thomas G. MAP2 kinase and 70K S6 kinase lie on distinct signalling pathways. Nature. 1991;349:348-350. [Medline] [Order article via Infotrieve]
24. Blenis J, Chung J, Erikson E, Alcorta DA, Erikson RL. Distinct mechanisms for the activation of the RSK kinases/MAP2 kinase/pp90rsk and pp70-S6 kinase signaling systems are indicated by inhibition of protein synthesis. Cell Growth Differ. 1991;2:279-285. [Abstract]
25. Chung J, Kuo CJ, Crabtree GR, Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70kd S6 protein kinases. Cell. 1992;69:1227-1236. [Medline] [Order article via Infotrieve]
26.
Price DJ, Grove JR, Calvo V, Avruch J, Bierer
BE. Rapamycin-induced inhibition of the 70-kilodalton S6
protein kinase. Science. 1992;257:973-977.
27. Snyder SH, Sabatini DM. Immunophilins and the nervous system. Nat Med. 1995;1:32-37. [Medline] [Order article via Infotrieve]
28. Lane HA, Fernandez A, Lamb NJ, Thomas G. p70s6k function is essential for G1 progression. Nature. 1993;363:170-172. [Medline] [Order article via Infotrieve]
29. Reinhard C, Fernandez A, Lamb NJC, Thomas G. Nuclear localization of p85s6k: functional requirement for entry into S phase. EMBO J. 1994;13:1557-1565. [Medline] [Order article via Infotrieve]
30.
Marx So, Jayaraman T, Go LO, Marks AR.
Rapamycin-FKBP inhibits cell cycle regulators of proliferation in
vascular smooth muscle cells. Circ Res. 1995;76:412-417.
31. Nigg EA. Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. Bioessays. 1995;17:471-480. [Medline] [Order article via Infotrieve]
32.
Bader D, Masaki T, Fischman DA. Immunochemical
analysis of myosin heavy chain during avian myogenesis in vivo
and in vitro. J Cell Biol. 1982;95:763-770.
33.
Pelech SL, Krebs EG.
Mitogen-activated S6 kinase is stimulated via protein
kinase C-dependent and independent pathways in Swiss 3T3 cells.
J Biol Chem. 1987;262:11598-11606.
34.
Flotow H, Thomas G. Substrate recognition
determinants of the mitogen-activated 70 K S6 kinase from
rat liver. J Biol Chem. 1992;267:3074-3078.
35.
Terada N, Franklin RA, Lucas JJ, Blenis J, Gelfand
EW. Failure of rapamycin to block proliferation once resting
cells have entered the cell cycle despite inactivation of p70 S6
kinase. J Biol Chem. 1993;268:12062-12068.
36. Jahn L, Sadoshima J, Izumo S. Cyclins and cyclin-dependent kinases are differentially regulated during terminal differentiation of C2C12 muscle cells. Exp Cell Res. 1994;212:297-307. [Medline] [Order article via Infotrieve]
37. Alexander DR, Graves JD, Lucas SC, Cantrell DA, Crumpton MJ. A method for measuring protein kinase C activity in permeabilized T lymphocytes by using peptide substrates: evidence for multiple pathways of kinase activation. Biochem J. 1990;268:303-308.[Medline] [Order article via Infotrieve]
38.
Wildenthal K, Wakeland JR, Morton PC, Griffin
EE. Inhibition of protein degradation in mouse hearts by agents
that cause lysosomal dysfunction. Circ
Res. 1978;42:787-792.
39.
McDonough PM, Brown JH, Glembotski CC.
Phenylephrine and endothelin differentially stimulate
cardiac PI hydrolysis and ANF expression. Am J
Physiol. 1993;264:H625-H630.
40.
Fauteck SP, Kandarian SC. Sensitive detection of
myosin heavy chain composition in skeletal muscle under different
loading conditions. Am J Physiol. 1995;268:C419-C424.
41.
Lompre AM, Nadal-Ginard B, Mahdavi V. Expression
of the cardiac ventricular alpha- and beta-myosin heavy
chain genes is developmentally and hormonally regulated.
J Biol Chem. 1984;259:6437-6446.
42. Brown EJ, Albers MW, Shin TB, Ichikawa K, Keith CT, Lane WS, Schreiber SL. A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. 1994;369:756-758. [Medline] [Order article via Infotrieve]
43. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell. 1994;78:35-43. [Medline] [Order article via Infotrieve]
44.
Blenis J, Erikson RL.
Phosphorylation of the ribosomal protein S6 is elevated
in cells transformed by a variety of tumor viruses.
J Virol. 1984;50:966-969.
45.
Jefferies HBJ, Reinhard C, Kozma SC, Thomas
G. Rapamycin selectively represses translation of the
`polypyrimidine tract' mRNA family. Proc Natl Acad Sci
U S A. 1994;91:4441-4445.
46.
Hu MC-T, Sharp SB, Davidson N. The complete
sequence of the mouse skeletal -actin gene reveals several
conserved and inverted repeat sequences outside of the
protein-coding region. Mol Cell Biol. 1986;6:15-25.
47.
Seidman CE, Duby A D., Choi E, Graham RM, Haber E,
Homcy C, Smith JA, Seidman JG. The structure of rat preproatrial
natriuretic factor as defined by a complementary DNA
clone. Science. 1984;225:324-326.
48.
Thompson WR, Nadal-Ginard B, Mahdavi V. A
myoD1-independent muscle-specific enhancer controls the expression
of the ß-myosin heavy chain gene in skeletal and cardiac muscle
cells. J Biol Chem. 1991;266:22678-22688.
49. Chung J, Grammer TC, Lemon KP, Kazlauskas A, Blenis J. PDGF- and insulin-dependent pp70S6K activation mediated by phosphatidylinositol-3-OH kinase. Nature. 1994;370:71-75. [Medline] [Order article via Infotrieve]
50. Ming X-F, Burgering BMT, Wennstrom S, Clasesson-Welsh L, Heldin C-H, Bos JL, Kozma SC, Thomas G. Activation of p70/85 S6 kinase by a pathway independent of p21ras. Nature. 1994;371:426-429. [Medline] [Order article via Infotrieve]
51.
Stephens L, Smrcka A, Cooke FT, Jackson TR, Sternweis
PC, Hawkins PT. A novel phosphoinositide 3
kinase in myeloid-derived cells is activated by G protein
ß subunits. Cell. 1994;77:83-93. [Medline]
[Order article via Infotrieve]
52.
Schunkert H, Sadoshima J, Cornelius T, Kagaya Y,
Weinberg EO, Izumo S, Riegger G, Lorell BH.
Angiotensin II–induced growth responses in isolated adult
rat hearts: evidence for load-independent induction of cardiac
protein synthesis by angiotensin II.
Circ Res. 1995;76:489-497.
53.
Haystead TAJ, Haystead CMM, Hu C, Lin T-A, Lawrence
JCJ. Phosphorylation of PHAS-I by
mitogen-activated protein (MAP) kinase: identification of a
site phosphorylated by MAP kinase in vitro and in
response to insulin in rat adipocytes. J Biol
Chem. 1994;269:23185-23191.
54.
Rao GN, Griendling KK, Frederickson RM, Sonenberg N,
Alexander RW. Angiotensin II induces
phosphorylation of eukaryotic protein
synthesis initiation factor 4E in vascular smooth muscle cells.
J Biol Chem. 1994;269:7180-7184.
This article has been cited by other articles:
 |
|
 |
|
  W.-H. Shen, Z. Chen, S. Shi, H. Chen, W. Zhu, A. Penner, G. Bu, W. Li, D. W. Boyle, M. Rubart, et al. Cardiac Restricted Overexpression of Kinase-dead Mammalian Target of Rapamycin (mTOR) Mutant Impairs the mTOR-mediated Signaling and Cardiac Function J. Biol. Chem., May 16, 2008; 283(20): 13842 - 13849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Yan, A. J. T. Schuldt, R. L. Price, I. Amende, F.-F. Liu, K. Okoshi, K. K. L. Ho, A. J. Pope, T. K. Borg, B. H. Lorell, et al. Pressure overload-induced hypertrophy in transgenic mice selectively overexpressing AT2 receptors in ventricular myocytes Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1274 - H1281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sharma, J. Masri, O. D. Jo, A. Bernath, J. Martin, A. Funk, and J. Gera Protein Kinase C Regulates Internal Initiation of Translation of the GATA-4 mRNA following Vasopressin-induced Hypertrophy of Cardiac Myocytes J. Biol. Chem., March 30, 2007; 282(13): 9505 - 9516. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Shiojima and K. Walsh Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway Genes & Dev., December 15, 2006; 20(24): 3347 - 3365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Tsujita, J. Muraski, I. Shiraishi, T. Kato, J. Kajstura, P. Anversa, and M. A. Sussman Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy PNAS, August 8, 2006; 103(32): 11946 - 11951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. Samuelsson, E. Bollano, R. Mobini, B.-M. Larsson, E. Omerovic, M. Fu, F. Waagstein, and A. Holmang Hyperinsulinemia: effect on cardiac mass/function, angiotensin II receptor expression, and insulin signaling pathways Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H787 - H796. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schoffstall, A. Kataoka, A. Clark, and P. B. Chase Effects of Rapamycin on Cardiac and Skeletal Muscle Contraction and Crossbridge Cycling J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 12 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G Proud Ras, PI3-kinase and mTOR signaling in cardiac hypertrophy Cardiovasc Res, August 15, 2004; 63(3): 403 - 413. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. McMullen, T. Shioi, L. Zhang, O. Tarnavski, M. C. Sherwood, A. L. Dorfman, S. Longnus, M. Pende, K. A. Martin, J. Blenis, et al. Deletion of Ribosomal S6 Kinases Does Not Attenuate Pathological, Physiological, or Insulin-Like Growth Factor 1 Receptor-Phosphoinositide 3-Kinase-Induced Cardiac Hypertrophy Mol. Cell. Biol., July 15, 2004; 24(14): 6231 - 6240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. McMullen, M. C. Sherwood, O. Tarnavski, L. Zhang, A. L. Dorfman, T. Shioi, and S. Izumo Inhibition of mTOR Signaling With Rapamycin Regresses Established Cardiac Hypertrophy Induced by Pressure Overload Circulation, June 22, 2004; 109(24): 3050 - 3055. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Frey, H. A. Katus, E. N. Olson, and J. A. Hill Hypertrophy of the Heart: A New Therapeutic Target? Circulation, April 6, 2004; 109(13): 1580 - 1589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. N. Olson and M. D. Schneider Sizing up the heart: development redux in disease Genes & Dev., August 15, 2003; 17(16): 1937 - 1956. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sanada, K. Node, T. Minamino, S. Takashima, A. Ogai, H. Asanuma, H. Ogita, Y. Liao, M. Asakura, J. Kim, et al. Long-Acting Ca2+ Blockers Prevent Myocardial Remodeling Induced by Chronic NO Inhibition in Rats Hypertension, April 1, 2003; 41(4): 963 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shioi, J. R. McMullen, O. Tarnavski, K. Converso, M. C. Sherwood, W. J. Manning, and S. Izumo Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in Mice Circulation, April 1, 2003; 107(12): 1664 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Depre, M. Hase, V. Gaussin, A. Zajac, L. Wang, L. Hittinger, B. Ghaleh, X. Yu, R. K. Kudej, T. Wagner, et al. H11 Kinase Is a Novel Mediator of Myocardial Hypertrophy In Vivo Circ. Res., November 29, 2002; 91(11): 1007 - 1014. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. D. Li, E. R. Block, and J. M. Patel Activation of multiple signaling modules is critical in angiotensin IV-induced lung endothelial cell proliferation Am J Physiol Lung Cell Mol Physiol, October 1, 2002; 283(4): L707 - L716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sanada, K. Node, H. Asanuma, H. Ogita, S. Takashima, T. Minamino, M. Asakura, Y. Liao, A. Ogai, J. Kim, et al. Opening of the adenosine triphosphate-sensitive potassium channel attenuates cardiac remodeling induced by long-term inhibition of nitric oxide synthesis: Role of 70-kDa S6 kinase and extracellular signal-regulated kinase J. Am. Coll. Cardiol., September 4, 2002; 40(5): 991 - 997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shioi, J. R. McMullen, P. M. Kang, P. S. Douglas, T. Obata, T. F. Franke, L. C. Cantley, and S. Izumo Akt/Protein Kinase B Promotes Organ Growth in Transgenic Mice Mol. Cell. Biol., April 15, 2002; 22(8): 2799 - 2809. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. C. Tu, J. J. Bahl, and Q. M. Chen Signals of Oxidant-Induced Cardiomyocyte Hypertrophy: Key Activation of p70 S6 Kinase-1 and Phosphoinositide 3-Kinase J. Pharmacol. Exp. Ther., March 1, 2002; 300(3): 1101 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhang Old and new tools to dissect calcineurin's role in pressure-overload cardiac hypertrophy Cardiovasc Res, February 1, 2002; 53(2): 294 - 303. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sanada, M. Kitakaze, K. Node, S. Takashima, A. Ogai, H. Asanuma, Y. Sakata, M. Asakura, H. Ogita, Y. Liao, et al. Differential Subcellular Actions of ACE Inhibitors and AT1 Receptor Antagonists on Cardiac Remodeling Induced by Chronic Inhibition of NO Synthesis in Rats Hypertension, September 1, 2001; 38(3): 404 - 411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Oh, G. E. Taffet, K. A. Youker, M. L. Entman, P. A. Overbeek, L. H. Michael, and M. D. Schneider Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival PNAS, August 17, 2001; (2001) 191169098. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yang, X. Wang, and M. K. Raizada Characterization of Signal Transduction Pathway in Neurotropic Action of Angiotensin II in Brain Neurons Endocrinology, August 1, 2001; 142(8): 3502 - 3511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. C. Braun-Dullaeus, M. J. Mann, U. Seay, L. Zhang, H. E. von der Leyen, R. E. Morris, and V. J. Dzau Cell Cycle Protein Expression in Vascular Smooth Muscle Cells In Vitro and In Vivo Is Regulated Through Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin Arterioscler Thromb Vasc Biol, July 1, 2001; 21(7): 1152 - 1158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Everett, T. D. Stoops, A. C. Nairn, and D. Brautigan Angiotensin II regulates phosphorylation of translation elongation factor-2 in cardiac myocytes Am J Physiol Heart Circ Physiol, July 1, 2001; 281(1): H161 - H167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wen, J. Gu, Y. Liu, P. H. Wang, Y. Sun, and J. L. Nadler Overexpression of 12-Lipoxygenase Causes Cardiac Fibroblast Cell Growth Circ. Res., January 19, 2001; 88(1): 70 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Leicht, N. Greipel, and H.-G. Zimmer Comitogenic effect of catecholamines on rat cardiac fibroblasts in culture Cardiovasc Res, November 1, 2000; 48(2): 274 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Govindarajan, D. M. Eble, P. A. Lucchesi, and A. M. Samarel Focal Adhesion Kinase Is Involved in Angiotensin II-Mediated Protein Synthesis in Cultured Vascular Smooth Muscle Cells Circ. Res., October 13, 2000; 87(8): 710 - 716. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Araki, K. Hasegawa, E. Iwai-Kanai, M. Fujita, T. Sawamura, T. Kakita, H. Wada, T. Morimoto, and S. Sasayama Endothelin-1 as a protective factor against beta-adrenergic agonist-induced apoptosis in cardiac myocytes J. Am. Coll. Cardiol., October 1, 2000; 36(4): 1411 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kodama, K. Fukuda, J. Pan, M. Sano, T. Takahashi, T. Kato, S. Makino, T. Manabe, M. Murata, and S. Ogawa Significance of ERK cascade compared with JAK/STAT and PI3-K pathway in gp130-mediated cardiac hypertrophy Am J Physiol Heart Circ Physiol, October 1, 2000; 279(4): H1635 - H1644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Pham, P. H. Sugden, and A. Clerk Regulation of Protein Kinase B and 4E-BP1 by Oxidative Stress in Cardiac Myocytes Circ. Res., June 23, 2000; 86(12): 1252 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. W. Kraiss, A. S. Weyrich, N. M. Alto, D. A. Dixon, T. M. Ennis, V. Modur, T. M. McIntyre, S. M. Prescott, and G. A. Zimmerman Fluid flow activates a regulator of translation, p70/p85 S6 kinase, in human endothelial cells Am J Physiol Heart Circ Physiol, May 1, 2000; 278(5): H1537 - H1544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O. Boluyt and O. H.L. Bing Matrix gene expression and decompensated heart failure: The aged SHR model Cardiovasc Res, May 1, 2000; 46(2): 239 - 249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kim and H. Iwao Molecular and Cellular Mechanisms of Angiotensin II-Mediated Cardiovascular and Renal Diseases Pharmacol. Rev., March 1, 2000; 52(1): 11 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Eguchi, H. Iwasaki, H. Ueno, G. D. Frank, E. D. Motley, K. Eguchi, F. Marumo, Y. Hirata, and T. Inagami Intracellular Signaling of Angiotensin II-induced p70 S6 Kinase Phosphorylation at Ser411 in Vascular Smooth Muscle Cells. POSSIBLE REQUIREMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR, RAS, EXTRACELLULAR SIGNAL-REGULATED KINASE, AND AKT J. Biol. Chem., December 24, 1999; 274(52): 36843 - 36851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Baliga, D. R. Pimental, Y.-Y. Zhao, W. W. Simmons, M. A. Marchionni, D. B. Sawyer, and R. A. Kelly NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase, p70S6K, and MEK-MAPK-RSK Am J Physiol Heart Circ Physiol, November 1, 1999; 277(5): H2026 - H2037. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Toyofuku, M. Yabuki, K. Otsu, T. Kuzuya, M. Tada, and M. Hori Functional Role of c-Src in Gap Junctions of the Cardiomyopathic Heart Circ. Res., October 15, 1999; 85(8): 672 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C Wollert and H. Drexler The renin-angiotensin system and experimental heart failure Cardiovasc Res, September 1, 1999; 43(4): 838 - 849. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Malhotra, J. Sadoshima, F. C. Brosius III, and S. Izumo Mechanical Stretch and Angiotensin II Differentially Upregulate the Renin-Angiotensin System in Cardiac Myocytes In Vitro Circ. Res., July 23, 1999; 85(2): 137 - 146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. GUMMERT, T. IKONEN, and R. E. MORRIS Newer Immunosuppressive Drugs: A Review J. Am. Soc. Nephrol., June 1, 1999; 10(6): 1366 - 1380. [Abstract] [Full Text]
|
|
|
|
|
|
E. N. Olson and J. D. Molkentin Prevention of Cardiac Hypertrophy by Calcineurin Inhibition : Hope or Hype? Circ. Res., April 2, 1999; 84(6): 623 - 632. [Full Text] [PDF]
|
|
|
|
|
|
R. H. Ritchie, J. D. Marsh, and R. J. Schiebinger Bradykinin-stimulated protein synthesis by myocytes is dependent on the MAP kinase pathway and p70S6K Am J Physiol Heart Circ Physiol, April 1, 1999; 276(4): H1393 - H1398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ehmke, J. Faulhaber, K. Munter, M. Kirchengast, and R. J. Wiesner Chronic ETA Receptor Blockade Attenuates Cardiac Hypertrophy Independently of Blood Pressure Effects in Renovascular Hypertensive Rats Hypertension, April 1, 1999; 33(4): 954 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kaburagi, K. Hasegawa, T. Morimoto, M. Araki, T. Sawamura, T. Masaki, and S. Sasayama The Role of Endothelin-Converting Enzyme-1 in the Development of {alpha}1-Adrenergic-Stimulated Hypertrophy in Cultured Neonatal Rat Cardiac Myocytes Circulation, January 19, 1999; 99(2): 292 - 298. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Baar and K. Esser Phosphorylation of p70S6k correlates with increased skeletal muscle mass following resistance exercise Am J Physiol Cell Physiol, January 1, 1999; 276(1): C120 - C127. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Abdellatif, S. E. Packer, L. H. Michael, D. Zhang, M. J. Charng, and M. D. Schneider A Ras-Dependent Pathway Regulates RNA Polymerase II Phosphorylation in Cardiac Myocytes: Implications for Cardiac Hypertrophy Mol. Cell. Biol., November 1, 1998; 18(11): 6729 - 6736. [Abstract] [Full Text]
|
|
|
|
|
|
M. O. Gray, C. S. Long, J. E. Kalinyak, H.-T. Li, and J. S. Karliner Angiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-{beta}1 and endothelin-1 from fibroblasts Cardiovasc Res, November 1, 1998; 40(2): 352 - 363. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tamura, N. Nyui, N. Tamura, T. Fujita, M. Kihara, Y. Toya, I. Takasaki, N. Takagi, M. Ishii, K.-i. Oda, et al. Mechanism of Angiotensin II-mediated Regulation of Fibronectin Gene in Rat Vascular Smooth Muscle Cells J. Biol. Chem., October 9, 1998; 273(41): 26487 - 26496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Laser, V. S. Kasi, M. Hamawaki, G. Cooper IV, C. M. Kerr, and D. Kuppuswamy Differential Activation of p70 and p85 S6 Kinase Isoforms during Cardiac Hypertrophy in the Adult Mammal J. Biol. Chem., September 18, 1998; 273(38): 24610 - 24619. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. A. Fischer, K. Singh, D. S. O'Hara, D. M. Kaye, and R. A. Kelly Role of AT1 and AT2 receptors in regulation of MAPKs and MKP-1 by ANG II in adult cardiac myocytes Am J Physiol Heart Circ Physiol, September 1, 1998; 275(3): H906 - H916. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kunapuli, J. A. Lawson, J. A. Rokach, J. L. Meinkoth, and G. A. FitzGerald Prostaglandin F2alpha (PGF2alpha ) and the Isoprostane, 8,12-iso-Isoprostane F2alpha -III, Induce Cardiomyocyte Hypertrophy. DIFFERENTIAL ACTIVATION OF DOWNSTREAM SIGNALING PATHWAYS J. Biol. Chem., August 28, 1998; 273(35): 22442 - 22452. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Ross, C. Pham, S.-Y. Shai, J. I. Goldhaber, C. Fenczik, C. C. Glembotski, M. H. Ginsberg, and J. C. Loftus ß1 Integrins Participate in the Hypertrophic Response of Rat Ventricular Myocytes Circ. Res., June 15, 1998; 82(11): 1160 - 1172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Kometiani, J. Li, L. Gnudi, B. B. Kahn, A. Askari, and Z. Xie Multiple Signal Transduction Pathways Link Na+/K+-ATPase to Growth-related Genes in Cardiac Myocytes. THE ROLES OF Ras AND MITOGEN-ACTIVATED PROTEIN KINASES J. Biol. Chem., June 12, 1998; 273(24): 15249 - 15256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Oh, Y. Fujio, K. Kunisada, H. Hirota, H. Matsui, T. Kishimoto, and K. Yamauchi-Takihara Activation of Phosphatidylinositol 3-Kinase through Glycoprotein 130 Induces Protein Kinase B and p70 S6 Kinase Phosphorylation in Cardiac Myocytes J. Biol. Chem., April 17, 1998; 273(16): 9703 - 9710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Aoki, S. Izumo, and J. Sadoshima Angiotensin II Activates RhoA in Cardiac Myocytes : A Critical Role of RhoA in Angiotensin II–Induced Premyofibril Formation Circ. Res., April 6, 1998; 82(6): 666 - 676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O. Boluyt, J.-S. Zheng, A. Younes, X. Long, L. O'Neill, H. Silverman, E. G. Lakatta, and M. T. Crow Rapamycin Inhibits {alpha}1-Adrenergic Receptor–Stimulated Cardiac Myocyte Hypertrophy but Not Activation of Hypertrophy-Associated Genes : Evidence for Involvement of p70 S6 Kinase Circ. Res., August 19, 1997; 81(2): 176 - 186. [Abstract] [Full Text]
|
|
|
|
|
|
R. W. Brownsey, A. N. Boone, and M. F. Allard Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms Cardiovasc Res, April 1, 1997; 34(1): 3 - 24. [Full Text] [PDF]
|
|
|
|
|
|
J. Sadoshima, H. Aoki, and S. Izumo Angiotensin II and Serum Differentially Regulate Expression of Cyclins, Activity of Cyclin-Dependent Kinases, and Phosphorylation of Retinoblastoma Gene Product in Neonatal Cardiac Myocytes Circ. Res., February 1, 1997; 80(2): 228 - 241. [Abstract] [Full Text]
|
|
|
|
|
|
T. Force, C. M. Pombo, J. A. Avruch, J. V. Bonventre, and J. M. Kyriakis Stress-Activated Protein Kinases in Cardiovascular Disease Circ. Res., June 1, 1996; 78(6): 947 - 953. [Full Text]
|
|
|
|
|
|
P. Paradis, W. R. MacLellan, N. S. Belaguli, R. J. Schwartz, and M. D. Schneider Serum Response Factor Mediates AP-1-dependent Induction of the Skeletal alpha-Actin Promoter in Ventricular Myocytes J. Biol. Chem., May 3, 1996; 271(18): 10827 - 10833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Wang, Y.-C. Zhu, and T. Yao Effects of all-trans retinoic acid on angiotensin II-induced myocyte hypertrophy J Appl Physiol, May 1, 2002; 92(5): 2162 - 2168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Laser, C. D. Willey, W. Jiang, G. Cooper IV, D. R. Menick, M. R. Zile, and D. Kuppuswamy Integrin Activation and Focal Complex Formation in Cardiac Hypertrophy J. Biol. Chem., November 3, 2000; 275(45): 35624 - 35630. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Young, F. A. Laws, G. W. Goodwin, and H. Taegtmeyer Reactivation of Peroxisome Proliferator-activated Receptor alpha Is Associated with Contractile Dysfunction in Hypertrophied Rat Heart J. Biol. Chem., November 21, 2001; 276(48): 44390 - 44395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Oh, G. E. Taffet, K. A. Youker, M. L. Entman, P. A. Overbeek, L. H. Michael, and M. D. Schneider Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy, and survival PNAS, August 28, 2001; 98(18): 10308 - 10313. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||